KR101634032B1 - 디메틸-벤조산 화합물 - Google Patents

디메틸-벤조산 화합물 Download PDF

Info

Publication number
KR101634032B1
KR101634032B1 KR1020147036136A KR20147036136A KR101634032B1 KR 101634032 B1 KR101634032 B1 KR 101634032B1 KR 1020147036136 A KR1020147036136 A KR 1020147036136A KR 20147036136 A KR20147036136 A KR 20147036136A KR 101634032 B1 KR101634032 B1 KR 101634032B1
Authority
KR
South Korea
Prior art keywords
methyl
dimethyl
mmol
amino
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147036136A
Other languages
English (en)
Korean (ko)
Other versions
KR20150013335A (ko
Inventor
마리아-지저스 블랑코-필라도
타티아나 나탈리 베트맨
매튜 조셉 피셔
스티븐 리 커클리쉬
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20150013335A publication Critical patent/KR20150013335A/ko
Application granted granted Critical
Publication of KR101634032B1 publication Critical patent/KR101634032B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
KR1020147036136A 2012-06-29 2013-06-20 디메틸-벤조산 화합물 Expired - Fee Related KR101634032B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261665956P 2012-06-29 2012-06-29
US61/665,956 2012-06-29
US201361778969P 2013-03-13 2013-03-13
US61/778,969 2013-03-13
PCT/US2013/046685 WO2014004230A1 (en) 2012-06-29 2013-06-20 Dimethyl-benzoic acid compounds

Publications (2)

Publication Number Publication Date
KR20150013335A KR20150013335A (ko) 2015-02-04
KR101634032B1 true KR101634032B1 (ko) 2016-06-27

Family

ID=48746667

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147036136A Expired - Fee Related KR101634032B1 (ko) 2012-06-29 2013-06-20 디메틸-벤조산 화합물

Country Status (40)

Country Link
US (2) US8642768B2 (cg-RX-API-DMAC10.html)
EP (1) EP2867218B1 (cg-RX-API-DMAC10.html)
JP (1) JP6114824B2 (cg-RX-API-DMAC10.html)
KR (1) KR101634032B1 (cg-RX-API-DMAC10.html)
CN (1) CN104334540B (cg-RX-API-DMAC10.html)
AP (1) AP4063A (cg-RX-API-DMAC10.html)
AR (1) AR091431A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013280779B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014029551A2 (cg-RX-API-DMAC10.html)
CA (1) CA2875572C (cg-RX-API-DMAC10.html)
CL (1) CL2014003537A1 (cg-RX-API-DMAC10.html)
CO (1) CO7160064A2 (cg-RX-API-DMAC10.html)
CR (1) CR20140554A (cg-RX-API-DMAC10.html)
CY (1) CY1118830T1 (cg-RX-API-DMAC10.html)
DK (1) DK2867218T3 (cg-RX-API-DMAC10.html)
DO (1) DOP2014000286A (cg-RX-API-DMAC10.html)
EA (1) EA025531B1 (cg-RX-API-DMAC10.html)
ES (1) ES2623099T3 (cg-RX-API-DMAC10.html)
GT (1) GT201400289A (cg-RX-API-DMAC10.html)
HR (1) HRP20170540T1 (cg-RX-API-DMAC10.html)
HU (1) HUE032398T2 (cg-RX-API-DMAC10.html)
IL (1) IL236218A (cg-RX-API-DMAC10.html)
IN (1) IN2014MN02356A (cg-RX-API-DMAC10.html)
JO (1) JO3221B1 (cg-RX-API-DMAC10.html)
LT (1) LT2867218T (cg-RX-API-DMAC10.html)
ME (1) ME02655B (cg-RX-API-DMAC10.html)
MX (1) MX347476B (cg-RX-API-DMAC10.html)
MY (1) MY172860A (cg-RX-API-DMAC10.html)
NZ (1) NZ701894A (cg-RX-API-DMAC10.html)
PE (1) PE20150185A1 (cg-RX-API-DMAC10.html)
PH (1) PH12015500008B1 (cg-RX-API-DMAC10.html)
PL (1) PL2867218T3 (cg-RX-API-DMAC10.html)
PT (1) PT2867218T (cg-RX-API-DMAC10.html)
RS (1) RS55756B1 (cg-RX-API-DMAC10.html)
SG (1) SG11201408629QA (cg-RX-API-DMAC10.html)
SI (1) SI2867218T1 (cg-RX-API-DMAC10.html)
TN (1) TN2014000500A1 (cg-RX-API-DMAC10.html)
TW (1) TWI572597B (cg-RX-API-DMAC10.html)
WO (1) WO2014004230A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201408631B (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015221A1 (en) * 2003-12-23 2011-01-20 Pierre Fabre Medicament Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
TWI572597B (zh) * 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
JP6200596B2 (ja) 2013-12-17 2017-09-20 イーライ リリー アンド カンパニー ジメチル安息香酸化合物
US10189788B2 (en) 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PE20191616A1 (es) * 2017-04-10 2019-11-05 Bayer Ag N-ariletil-2-arilquinolina-4-carboxamidas sustituidas y su uso
TWI770157B (zh) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
JP7816164B2 (ja) 2020-11-13 2026-02-18 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
JP2000355551A (ja) * 1999-06-15 2000-12-26 Nikken Chem Co Ltd 医薬組成物
MXPA06003123A (es) 2003-09-22 2006-05-31 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor.
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
KR20090122931A (ko) * 2007-03-26 2009-12-01 아스테라스 세이야쿠 가부시키가이샤 오르니틴 유도체
WO2012004293A2 (de) 2010-07-08 2012-01-12 Bayer Cropscience Ag Insektizide und fungizide wirkstoffkombinationen
CA2831978A1 (en) 2011-03-03 2012-09-07 Universitat Des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
TWI572597B (zh) * 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基-苯甲酸化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands

Also Published As

Publication number Publication date
ES2623099T3 (es) 2017-07-10
HUE032398T2 (en) 2017-09-28
ZA201408631B (en) 2017-04-26
CR20140554A (es) 2015-02-04
US8933098B2 (en) 2015-01-13
NZ701894A (en) 2016-09-30
SG11201408629QA (en) 2015-01-29
CN104334540A (zh) 2015-02-04
HK1203936A1 (en) 2015-11-06
KR20150013335A (ko) 2015-02-04
AP2014008165A0 (en) 2014-12-31
EA201492140A1 (ru) 2015-10-30
WO2014004230A1 (en) 2014-01-03
BR112014029551A2 (pt) 2017-06-27
MX2014015952A (es) 2015-07-17
CA2875572C (en) 2016-03-22
AP4063A (en) 2017-03-09
PE20150185A1 (es) 2015-02-13
JP2015522589A (ja) 2015-08-06
JP6114824B2 (ja) 2017-04-12
CA2875572A1 (en) 2014-01-03
CN104334540B (zh) 2016-03-16
EP2867218A1 (en) 2015-05-06
IL236218A0 (en) 2015-02-01
TN2014000500A1 (en) 2016-03-30
CO7160064A2 (es) 2015-01-15
TW201410665A (zh) 2014-03-16
TWI572597B (zh) 2017-03-01
HRP20170540T1 (hr) 2017-06-16
MX347476B (es) 2017-04-27
IN2014MN02356A (cg-RX-API-DMAC10.html) 2015-08-14
SI2867218T1 (sl) 2017-04-26
GT201400289A (es) 2015-05-28
MY172860A (en) 2019-12-12
PL2867218T3 (pl) 2017-07-31
IL236218A (en) 2017-12-31
AU2013280779A1 (en) 2014-11-27
AU2013280779B2 (en) 2015-09-10
PT2867218T (pt) 2017-04-19
RS55756B1 (sr) 2017-07-31
JO3221B1 (ar) 2018-03-08
US20140094491A1 (en) 2014-04-03
US20140005222A1 (en) 2014-01-02
ME02655B (me) 2017-06-20
PH12015500008A1 (en) 2015-03-02
DK2867218T3 (en) 2017-05-01
EA025531B1 (ru) 2017-01-30
EP2867218B1 (en) 2017-02-22
CY1118830T1 (el) 2018-01-10
DOP2014000286A (es) 2015-01-31
CL2014003537A1 (es) 2015-04-24
AR091431A1 (es) 2015-02-04
US8642768B2 (en) 2014-02-04
LT2867218T (lt) 2017-04-25
PH12015500008B1 (en) 2015-03-02

Similar Documents

Publication Publication Date Title
KR20150013335A (ko) 디메틸-벤조산 화합물
KR101653476B1 (ko) 페녹시에틸 피페리딘 화합물
EP3083554B1 (en) Dimethylbenzoic acid compounds
KR101807981B1 (ko) 페녹시에틸 시클릭 아민 유도체 및 ep4 수용체 조절제로서의 그의 활성
JP2004512324A (ja) Nmda受容体拮抗剤としてのアミド誘導体
US9000043B2 (en) Phenoxyethoxy compounds
KR101798315B1 (ko) 페녹시에틸 디히드로-1h-이소퀴놀린 화합물
EA022043B1 (ru) Сульфоновые соединения в качестве лигандов 5-htрецептора
HK1203936B (en) Dimethyl-benzoic acid compounds useful for the treatment of inflammatory conditions
AU2014265762B2 (en) Phenoxyethyl dihydro-1H-isoquinoline compounds

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210622

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210622